Liposomal cyclosporin pharmaceutical formulation
AssigneeNeXstar Pharmaceuticals, Inc.
InventorsJill P. Adler-Moore, Su-Ming Chiang
Life of this patent
Estimating the term…
Abstract
An improved liposomal cyclosporin therapeutic formulation, comprising phosphatidylcholine, phosphatidylglycerol and a cyclosporin in a mole ratio of from 25:3:1 to 17:3:1 is described. The formulation includes unilamellar vesicles having reduced toxicity. The formulation is used as an immunosuppressive agent and is an enhancer of the efficacy of antineoplasties for drug resistant cancer cells. A method is also provided for inhibiting the growth of cancer cells.
Claims5
Therapeutic liposomes having a mean diameter size less than 45 nm comprising a phosphatidylcholine, dimyristoylphosphatidylglycerol and a cyclosporin in a mole ratio of from about 25:3:1 to about 17:3:1, wherein the liposomes are unilamellar and wherein the percent entrapped cyclosporin is about 85% or greater.
Dependencies are inferred from the claim text.